article · PLoS ONE
OBJECTIVE: This study aimed to examine treatment modalities, outcomes, and factors associated with in-hospital survival among people with HIV (PHIV) diagnosed with cryptococcal meningitis (CM) in Tanzania. METHODS: This hospital-based cross-sectional study retrospectively reviewed records of PHIV admitted to medical wards at Dodoma and Singida Regional Referral Hospitals in Tanzania from July 2019 to June 2024. Data on socio-demographics, antiretroviral therapy (ART) status, CD4 count, treatment, and outcomes were extracted using a standardised data collection tool. The primary outcome was in-hospital survival (discharged alive vs died). Descriptive statistics summarised patient characteristics, and modified Poisson regression with robust variance estimated adjusted risk ratios (aRR) for factors associated with being discharged alive. RESULTS: A total of 159 PHIV with CM records were reviewed. Of these, 89 (56.0%) were aged 36-55 years, 89 (56.0%) were female, and 138 (86.8%) were in WHO clinical stage IV. Of 159 patients, 88 (55.3%) received fluconazole monotherapy. In-hospital mortality among CM patients was 65 (46.5%). Discharge alive occurred in 61/73 (83.6%) of those on amphotericin B-based regimens versus 13/66 (19.7%) on fluconazole monotherapy. Patients treated with amphotericin B-based regimens were four times more likely to be discharged alive compared to those on fluconazole monotherapy (aPR = 4.19, 95% CI: 2.46-7.16, p < 0.001). CONCLUSION: CM remains a leading opportunistic infection causing high mortality among PHIV, with most patients managed using fluconazole monotherapy. In-hospital survival was significantly higher with amphotericin B-based regimens, highlighting the need to align practice with guideline recommendations. Further qualitative research is warranted to explore barriers to implementing recommended CM treatment.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1371/journal.pone.0332786
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.